# The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke

Study · id `cardio:ct-nct02452502` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02452502](<https://clinicaltrials.gov/study/NCT02452502>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02452502

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

## Technical summary

Registry record NCT02452502. Randomized; no masking; primary purpose treatment. Start 2015-09-02 (actual); primary completion 2017-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 254 participants (enrolled count; ClinicalTrials.gov record NCT02452502, source copy `cardio:ctgov-nct02452502-2020-03-31`, retrieved 2026-10-26)
- Started: 2015-09-02 (actual) (ClinicalTrials.gov record NCT02452502, source copy `cardio:ctgov-nct02452502-2020-03-31`, retrieved 2026-10-26)
- Primary completion: 2017-11 (actual) (ClinicalTrials.gov record NCT02452502, source copy `cardio:ctgov-nct02452502-2020-03-31`, retrieved 2026-10-26)
- Completion: 2018-08 (actual) (ClinicalTrials.gov record NCT02452502, source copy `cardio:ctgov-nct02452502-2020-03-31`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02452502, source copy `cardio:ctgov-nct02452502-2020-03-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02452502-2020-03-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke
- Acronym: SEATIS
- Condition: Stroke
- Intervention (Device): atorvastatin
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER
- Collaborator: The First Hospital of Jilin University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)
- Registry lists this organization as a collaborator: The First Hospital of Jilin University (`cardio:org-the-first-hospital-of-jilin-university`)

## Provenance

Content hash: 7b6dff4a5bad8a2654a5b4fd016abef4aab3eb4b9cc2e93c5fb1b87d9e2e990d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
